Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Abstract Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sought to assess the glycemic effects of sacubitril/valsartan in heart failu...

Full description

Bibliographic Details
Main Authors: Magnus O. Wijkman, Brian Claggett, Muthiah Vaduganathan, Jonathan W. Cunningham, Rasmus Rørth, Alice Jackson, Milton Packer, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Sanjiv J. Shah, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Cardiovascular Diabetology
Subjects:
Heart failure
Diabetes
Sacubitril/valsartan
Hypoglycemia
Online Access:https://doi.org/10.1186/s12933-022-01545-1

Internet

https://doi.org/10.1186/s12933-022-01545-1

Similar Items